CST BLOG

The official blog of Cell Signaling Technology, where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Hallmarks of Cancer: Inducing Angiogenesis Energetics

Read More
All Posts

Cancer cells stimulate the growth of blood vessels to supply nutrients to tumors. Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. This plays an important role in tumor growth.

18-CEL-47663-Blog-Hallmarks-Cancer-3-Inducing-Angiogenesis

The Hallmarks of Cancer were identified by Doctors Robert Weinberg and Douglas Hanahan and were originally published in Cell1. The authors propose the idea that the complexity of cancer can be broken down into smaller subsets of underlying principles. The information here pertains to one such subset. Other entries in this series explore the other known Hallmarks.

Inducing or Accessing Vasculature (Angiogenesis)

Benign tumors can exist in a dormant state, which can be driven by inadequate access to sufficient blood supply. However, the "angiogenic switch" occurs when angiogenesis is activated in a dormant tumor and growth factors are secreted to induce sprouting and chemotaxis of endothelial cells toward the tumor mass.

Within the hypoxic environment of the tumor mass, hypoxia inducible factor-1 (HIF-1) is stabilized and activates the expression of multiple genes contributing to the angiogenic process, including vascular endothelial growth factor (VEGF) and fibroblast growth factor (bFGF), or platelet-derived growth factor (PDGF).

Click the angiogenesis pathway link to learn more about the related proteins implicated in this Hallmark of Cancer:

Additional Resources

Read the additional blog posts in the Hallmarks of Cancer series to learn more:

  1.  Hanahan D, Weinberg RA (January 2000). "The Hallmarks of Cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9
  2. Hanahan D, Weinberg RA (March 2011). "Hallmarks of Cancer: the next generation". Cell. 144 (5):646-74. doi: 10.1016/j.cell.2011.02.013.
Chris Sumner
Chris Sumner
Chris Sumner was a writer at CST.

Recent Posts

Protect Your Drug Development Pipeline: Don't Let Antibody Supply Disrupt Your Progress

For many researchers, choosing the right antibody for a project is one of the most important parts of exp...
Josh Nathan Sep 10, 2025

ELISA Kit Lot-to-Lot Reproducibility: Safeguard the Quality of Your Data

Over the past eight years working as a Product Scientist at CST, a big part of my role has been to test o...
Emily Estabrook Aug 27, 2025

Hallmarks of Cancer: Genome Instability and Mutation

Genetic alterations are a fundamental characteristic of cancer. When DNA mutations and chromosomal rearra...
Susan Keezer, PhD Aug 20, 2025